← All causality assessments
Causality: well established
Causality assessment · Causality: well established
Metronidazole and Drug Hypersensitivity: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Metronidazole ↔ Drug Hypersensitivity
n=3,150 co-reports · PRR 5.4 · ROR 5.7
Ropeginterferon alfa-2b is a pegylated interferon for myelofibrosis. Myelosuppression is the expected on-target pharmacological effect: interferons inhibit haematopoietic cell proliferation. 434 co-reports (PRR 68.1) reflect both therapeutic effect and overlapping toxicity.
Label: ropeginterferon PI (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 68.1 with 434 co-reports |
| Consistency | met | Reproduced across interferon class |
| Specificity | partial | Specific to type I interferons |
| Biological gradient | met | Correlates with dose and duration |
| Plausibility | met | Known interferon mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Similar to other peginterferons |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Metronidazole captured drug hypersensitivity as a tracked adverse event in a usable structure. Myelosuppression is routinely monitored as a haematological AE in interferon trials.